Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: Absence of prognostic correlations

Leukemia and Lymphoma

Volumn 27, Issue 5-6, 1997, Pages 517-521

  Munker, Reinhold ^a,b   Younes, Anas ^b   Cabanillas, Fernando ^b   Andreeff, Michael ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Intermediate and low grade lymphomas; Prognosis; Soluble CD95

Indexed keywords

FAS ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SERUM;

EID: 0031461049     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058319     Document Type: Article

References (21)

1. Harris, N. L., Jaffe, E. S., Stein, H. et al. (1993). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84, 1361-1392.
2. International Non-Hodgkin's lymphoma prognostic factors project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl, J. Med., 329, 987-994.
3. Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M. and Kurzrock, R. (1995). Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J. Clin. Oncol., 13, 575-582.
4. Cortes, J. E., Talpaz, M., Cabanillas, F., Seymour, J. F. and Kurzrock, R. (1995). Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood, 85, 2516-2520.
5. Smith, C. A., Farrah, T. and Goodwill, R. G. (1994). The TNF receptor superfamily of cellular and viral proteins: activation. costimulation, and death. Cell. 76, 959-962.
6. Dhein, J., Walczak, H., Baumler, C., Debatin, K. M. and Krammer, P. H. (1995). Autocrine T-cell suicide mediated by Apo-1 (Fas/CD95). Nature, 373, 438-441.
7. Owen-Schaub, L., Yonehara, S., Grump, W. L. and Grimm, E. A. (1992). DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol., 140, 197-140.
8. Reed, J. C. (1995). Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hem/Onc Clin NA., 9, 451-473.
9. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J. and Mountz, J. D. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule, Science, 263, 1759-1762.
10. Cascino, I., Fiucci, G., Papoff, G. and Ruherti, G. (1995). Three functional soluble forms of the human apoptosisinducing Fas molecule are produced by alternative splicing. J Immunol., 154, 2706-2713.
11. Knipping, E., Dehatin, K. M., Stricker, K., Heilig, B., Eder, A. and Krammer, P. H. (1995). Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood, 85, 1562-1569.
12. Salles, G., Bienvenu, J., Bastion, Y., Barbier, Y., Doche, C., Warzocha, K., Gutowski, M. C., Rieux, C., and Coiffier, B. (1996). Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Brit. J. Haematol., 93, 352-359.
13. Denz, H., Orth, B., Weiss, G., Gallati, H., Herrmann, R., Huber, P., Wachter, H. and Fuchs. D. (1993). Serum soluble tumour necrosis factor 55 is increased in patients with haemalological neoplasias and is associated with immune activation and weight loss. Eur. J. Cancer, 16, 2232-2235.
14. + anaplastic large-cell lymphoma. J. Clin. Oncol., 13, 1355-1360.
15. Motokura, T., Kobayashi, Y., Fujita, A., Nakamura, Y., Taniguchi, T., Uchimaru, K. and Ansano, S. (1995). Clinical relevance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leukemia and Lymphoma. 16, 355-362.
16. Stasi, R., Zinzani, P. L., Galieni, P., Lauta, V. M., Damasio, E., Dispensa, E., Dammaco, F., Papa, G. and Tura, S. (1994). Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Brit. J. Haematol., 88, 770-777.
17. Lavabre-Bertrand, T., Exbrayat, C. Liautard, J., Gaillard, J. P., Baskevitch, P. P., Poujol, N., Duperay, C., Bourquard, P. and Brochier, J. (1995). Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies, Brit. J. Haematol., 91, 871-877.
18. Munker, R., Dimis, G., Owen-Schauh, L. and Andreeff, M. (1996). Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias. myeloproliferative and myclodysplastic syndromes. Leukemia, 10, 1531-1533.
19. Kondo, E., Yoshino, T., Yamadori, I., Matsuo, Y., Kawasaki, N., Minowada, J. and Akagi. T. (1994). Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol., 145, 330-337.
20. Nishiuchi, R., Yoshino, T., Matsuo, Y., Sakuma, I., Cao, L., Seino, Y., Takahashi, K. and Akagi, T. (1996). The Fas antigen is detected on immature B cells and the representative cell lines show Fas-mediated apoptosis. Brit. J. Haematol, 92, 302-307.
21. Danis V. A., Millington, M., Hyland, V. J., Grennan, D. (1995). Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-IrA) gene polymorphism. Clin Exp Immunol., 99, 303-310.